Phase II / III Clinical Research · Manhattan
A dedicated research site built for precise, fast, sponsor-ready trial execution.
Iteryx Clinical Research is a standalone Phase II/III site in New York, led by an experienced principal investigator and purpose-built for MASLD, metabolic, and gastrointestinal trials.
Enrolling a participant community as diverse as New York — across all five boroughs.
For participants
Join a study. Help move medicine forward.
Study-related visits and care are provided at no cost, and compensation for time and travel may be available. Participation is always voluntary, and you can withdraw at any time.
How it works
A short, no-obligation screening confirms whether a current study is a fit. We explain every step before anything begins.
What to expect
Scheduled visits, close monitoring by experienced study staff, and clear information at every stage of the trial.
Why participate
Access to investigational studies, attentive medical oversight, and a direct role in advancing care for your community.
What we offer
A site engineered for clean, credible trial conduct.
From recruitment to regulatory readiness, Iteryx is structured to give sponsors confidence and speed from feasibility through close-out.
Dedicated Phase II/III site
Purpose-built research space in Manhattan, operationally independent and structured around trial workflow — not a clinic running studies on the side.
Experienced principal investigator
A PI with a record across 30+ industry-sponsored trials, anchored in obesity, metabolic disease, and MASLD.
MRI-PDFF imaging network
MRI-PDFF for non-invasive fat quantification via ACR-accredited radiology partners across Manhattan, Queens, and Brooklyn, with on-site FibroScan and access to MR-elastography and ultrasound — and, through the PI's Mount Sinai faculty affiliation, access to academic research imaging for protocols that require it.
Article 28 ambulatory surgery center
Steps from the site: a New York State Article 28-licensed ambulatory surgery center for gastrointestinal diagnostic procedures — upper endoscopy, colonoscopy, and ultrasound-guided percutaneous liver biopsy — across two Manhattan locations, Northern Manhattan and Midtown, for broad participant access.
CLEP-permitted histopathology lab
Specimen processing supported by a New York State CLEP-permitted (CLIA-equivalent) histopathology laboratory for protocol biopsies and tissue specimens.
Regulatory & quality
Central IRB-ready, ICH-GCP–trained personnel, and an inspection-ready regulatory architecture and SOP framework.
Therapeutic focus
Depth where it matters most.
Primary strength
MASLD / MASH & Metabolic
The core of our principal investigator's trial experience, supported by on-site non-invasive staging and a deep metabolic patient base.
- Steatohepatitis & fibrosis-staged populations
- MRI-PDFF and MR-elastography workflows
- Cardiometabolic and adjacent endpoints
Speed lane
Gastroenterology & IBD
Built on an established GI patient panel, enabling fast identification and enrollment for inflammatory bowel disease and broader GI protocols.
- Ulcerative colitis & Crohn's disease
- Established GI patient base for efficient identification
- General gastroenterology protocols
Representation & reach
Enrollment as diverse as New York itself.
Iteryx draws on one of the most diverse patient communities in the country — immigrant, Hispanic/Latino, Afro-Caribbean, Black, Asian, and multiethnic New Yorkers across all five boroughs. That means representative trial populations many sites can’t reach — helping sponsors meet diversity-enrollment goals while ensuring findings reflect the patients these therapies are ultimately intended to serve. Rooted in Washington Heights and accessible citywide by subway and bus.
For trial sponsors
Why is Iteryx the right choice for sponsors of pharmaceutical-driven clinical trials?
The right population, reached the right way. Iteryx sits in a position few research sites can replicate: a dedicated Phase II/III site embedded in a community whose diversity mirrors New York City itself — turning representation into statistical power and scientific precision for the protocols we run.
Diversity as scientific signal
Representation that strengthens the data.
For obesity, metabolic, and MASLD protocols, diversity is more than a recruitment metric. Disease prevalence, rate of progression, and treatment response vary across ancestral and metabolic phenotypes — and the populations most underrepresented in trials are often those in whom these conditions are most prevalent and most severe. A cohort that mirrors New York strengthens the generalizability of efficacy and safety findings and meets the diversity-of-enrollment expectations sponsors now carry into regulatory submissions.
Trust as a conduit to precision
The right patients, well characterized.
Representation only matters if the population can be reached. An established practice with deep community presence and patient trust becomes a conduit to recruitment that is both representative and precise — enabling careful, well-phenotyped selection over cold outreach, reducing screen-failure friction, and protecting the retention that preserves statistical power through to database lock.
Leadership
Investigator-led, sponsor-minded.
Lincoln Hernandez, MD
Founder · Principal Investigator · Medical Director
Dr. Hernandez is a board-certified gastroenterologist with more than 20 years of experience and an Assistant Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai and an attending physician at The Mount Sinai Hospital.
He trained in Internal Medicine at NYU Downtown Hospital — earning the Program Director's Award and the John T. Flynn Young Investigator Award — completed a Clinical Nutrition fellowship at NewYork-Presbyterian Hospital / Columbia University Medical Center, where he was a research fellow at Columbia's Celiac Disease Center and co-authored multiple peer-reviewed publications, and completed his gastroenterology fellowship at Tulane University School of Medicine.
He has served as Principal Investigator across 30+ industry-sponsored clinical trials, with his most recent clinical research focused on obesity, metabolic disease, and MASLD (metabolic dysfunction–associated steatotic liver disease) — including multiple MASLD/MASH drug studies. His broader gastroenterology expertise spans inflammatory bowel disease, celiac disease, and advanced endoscopy. He founded Iteryx to bring that experience into a dedicated, sponsor-ready research site.
495 Fort Washington Ave · Washington Heights
Get in touch
Considering a site for your next protocol?
We welcome feasibility inquiries from sponsors and CROs, and questions from prospective participants. Tell us about your study and we'll respond promptly.